Bristol’s Orencia sBLA For Juvenile Idiopathic Arthritis Accepted For FDA Review

U.K.’s NICE, meanwhile, concludes the biologic is not cost effective for treatment of rheumatoid arthritis following a TNF inhibitor.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet